A large-scale human trial of Moderna’s mRNA seasonal flu vaccine yielded mixed interim results in terms of effectiveness and safety, the company said Thursday.
The experimental vaccine, called mRNA-1010, is developed using the same technology as Moderna’s COVID-19 vaccines. It works by instructing the body’s cells to assemble hemagglutinin, a protein on the surface of the virus, to trigger an immune response and prepare the body to protect itself from future exposure.
